European Archives - Page 996 of 1053 - European Medical Journal

EMJ

Obesity and Mood Disorders Increase Peripartum Cardiomyopathy Risk

Seville, Spain – 23 May 2015: Obesity and mood disorders increase the risk of peripartum cardiomyopathy (PPCM) during childbirth, reveals research…

EMJ

TITRATION Study Confirms LCZ696 Safe and Tolerated in Clinical Practice

Seville, Spain – 23 May 2015: The TITRATION study has confirmed that LCZ696 is safe and tolerated by patients with heart failure and reduced…

EMJ

Cardiovascular Nurses Discuss the Latest in Evidence Based Care

Sophia Antipolis, 24 May 2015 – The cardiovascular nursing event of the year is heading south to Croatia. EuroHeartCare is the official annual meeting of…

EMJ

STOP-HF: Gene Therapy SDF-1 Remodels Hearts of High Risk Heart Failure Patients

Seville, Spain – 25 May 2015: The gene therapy SDF-1 remodelled the hearts of high risk heart failure patients in the phase II STOP-HF trial…

EMJ

Conservative Management of Prostate Cancer: Favourable 15-Year Outcomes in Older Patients with Low-Risk Disease

SURVIVAL outcomes among patients with low-risk prostate cancer (PrC) are favourable when initially treated with conservative management…

EMJ

Widespread Belief of Urine Sterility Put to the Sword

BACTERIA have been found in the bladders of healthy women, dispelling the myth that normal urine is sterile, according to new research from…

EMJ

Data Presented on Orsiro Hybrid Drug – El uting Stent at EuroPCR 2015 Highlights Safety and Efficacy in High – Risk Patients

PARIS, France, May 20, 2015—BIOTRONIK, a leading manufacturer of cardio- and endovascular medical technology, today hosted a…

EMJ

PARP inhibitors and the EMBRACA study of talazoparib in BRCA-related metastatic breast cancer

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Peter Fasching (Friedrich-Alexander-Universität Erlangen-Nürnberg…

EMJ

The mechanisms of BRCA-related breast cancer and molecular profiling

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Michael Untch (HELIOS Klinikum Berlin-Buch, Berlin, Germany) and Prof…

EMJ

Current research into treatments for BRCA-related breast cancer and the phase 3 EMBRACA trial

Dr Kelly focuses on the phase 3 EMBRACA study, which is evaluating the PARP inhibitor, talazoparib, versus physician’s choice in patients with locally advanced and/or metastatic BRCA-related breast cancer.